Expression profiles of GPR21, GPR39, GPR135, and GPR153 orphan receptors in different cancers.


Journal

Nucleosides, nucleotides & nucleic acids
ISSN: 1532-2335
Titre abrégé: Nucleosides Nucleotides Nucleic Acids
Pays: United States
ID NLM: 100892832

Informations de publication

Date de publication:
2022
Historique:
pubmed: 14 1 2022
medline: 12 2 2022
entrez: 13 1 2022
Statut: ppublish

Résumé

Orphan receptors have unknown endogenous ligands, are expressed in different tissues, and participate in various diseases such as diabetes, hypertension and cancer. We studied the expression profiles of GPR21, GPR39, GPR135 and GPR153 orphan receptors in several tumour tissues. Cervical, breast, skin, prostate, and astrocytoma tissues were analysed for orphan receptor gene expression using Real time PCR analysis. GPR39 is over-expressed in cervical and prostate cancer tissues, and GPR21 and GPR135 receptors are significantly decreased in cervical, breast, skin, prostate, and astrocytoma tissues, when compared with healthy human fibroblasts. In conclusion, GPR21 and GPR135 receptor gene expression is reduced in cancerous tissues. GPR39 may have a role in the development and evolution of cervical and prostate cancer. These data suggest these receptors may be alternative molecules for new diagnostic approaches, and the design of novel therapeutics against oncological pathologies.

Identifiants

pubmed: 35021931
doi: 10.1080/15257770.2021.2002892
doi:

Substances chimiques

GPR135 protein, human 0
GPR21 protein, human 0
GPR39 protein, human 0
Gpr153 protein, human 0
Ligands 0
Receptors, G-Protein-Coupled 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123-136

Auteurs

Juan René Gutiérrez-Ruiz (JR)

Escuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México.
Secretaria de Salud del estado de Chiapas, Tuxtla Gutiérrez, Chiapas, México.

Santiago Villafaña (S)

Escuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México.

Armando Ruiz-Hernández (A)

Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Baja California, Mexicali, Baja California, México.

Diocelina Viruette-Pontigo (D)

Secretaria de Salud del estado de Chiapas, Tuxtla Gutiérrez, Chiapas, México.

Celestina Menchaca-Cervantes (C)

Secretaria de Salud del estado de Chiapas, Tuxtla Gutiérrez, Chiapas, México.

Karla Aidee Aguayo-Cerón (KA)

Escuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México.

Fengyang Huang (F)

Departamento de Investigación en Farmacología, Hospital Infantil de México Federico Gómez, Ciudad de México, México.

Enrique Hong (E)

Departamento de Farmacobiología sede Sur, CINVESTAV, Ciudad de México, México.

Rodrigo Romero-Nava (R)

Escuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Ciudad de México, México.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH